Bacteria: Gram-negative

Klebsiella pneumoniae

General medical information for education only, not medical advice. Treatment considerations summarize published guidance at drug-class level; therapy is chosen by the treating clinician using susceptibility results, local resistance patterns and current guidelines.

Overview

An encapsulated gut organism and a major cause of healthcare-associated infection, frequently carrying resistance genes. Hypervirulent strains can cause invasive community infection.

Infections

Urinary tract infection, pneumonia (including aspiration and ventilator-associated), bloodstream infection, liver abscess, wound infection.

Signs and symptoms

Urinary symptoms; pneumonia with fever, productive cough and shortness of breath; fever and rigors in bloodstream infection.

Antibiotic and antimicrobial resistance

Often carries ESBL genes (ESBL genes); KPC and other carbapenemases (carbapenemases) make it a prominent example of carbapenem-resistant Enterobacterales (CRE).

Treatment considerations

Guided by susceptibility testing. ESBL producers are usually treated with a carbapenem; carbapenemase producers need newer agents selected with infectious-diseases or pharmacy input.

Infection control and public health

Carbapenemase-producing strains require contact precautions and public-health notification in many jurisdictions.

Klebsiella pneumoniae colonies on MacConkey agar
Klebsiella pneumoniae colonies on MacConkey agar. CDC PHIL; public domain. Image source
Gram-negative rods, schematic
Gram-negative rods. Schematic, not to scale; InnovexLab.

Sources

  1. CDC. Klebsiella.
  2. CDC. ESBL-producing Enterobacterales.
  3. CDC. Carbapenem-resistant Enterobacterales (CRE).
  4. IDSA. Guidance on the Treatment of Antimicrobial-Resistant Gram-Negative Infections.
  5. IDSA. Complicated Urinary Tract Infections guideline.

Sources accessed November 2026. Links open external sites that InnovexLab does not control.

Medical disclaimer

This page is general educational information summarized from published public-health and professional-society guidance. It is not medical advice, a diagnosis or a treatment recommendation, and reading it does not create a clinician–patient relationship with InnovexLab. Decisions about testing, diagnosis and treatment belong to the treating clinician, using the patient’s history and examination, laboratory and susceptibility results, local resistance patterns and current guidelines. Guidance changes over time; consult the original sources for the latest version. InnovexLab provides this information as is and does not warrant that it is complete or current.

Patients with questions about their health should contact their own healthcare provider. In an emergency, call 911.

Sources, image credits and editorial policy

Discuss a testing program with InnovexLab

Review the panel that fits your patients, its specimen requirements, and how results and billing work.